AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6468776 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pass filtered noise with cutoff frequency of 500 Hz
Number of subjects: 18
Study 6468776 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pass filtered noise with cutoff frequency of 1000 Hz
Number of subjects: 18
Study 6468776 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pass filtered noise with cutoff frequency of 2000 Hz
Number of subjects: 18
Study 6468776 — intervention group
Group type: EXPERIMENTAL
Intervention: Wider band signals
Number of subjects: 18
Study 6468776 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower frequency signals
Number of subjects: 18
Study 30882477 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy
Number of subjects: 30
Study 30882477 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen
Number of subjects: 30
Study 30882477 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive ventilation
Number of subjects: 30
Study 30005270 — intervention group
Group type: EXPERIMENTAL
Intervention: High-value penalty
Number of subjects: 78
Study 30005270 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-value penalty
Number of subjects: 78
Study 30005270 — intervention group
Group type: EXPERIMENTAL
Intervention: High-value reward
Number of subjects: 78
Study 30005270 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-value reward
Number of subjects: 78
Study 26414418 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 593
Study 26414418 — intervention group
Group type: COMPARATOR
Intervention: Control group (middle school as usual)
Number of subjects: 593
Study 24472622 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (2 mA) with anode over PZ and cathode over AF4 (P+F‐)
Number of subjects: 16
Study 24472622 — intervention group
Group type: COMPARATOR
Intervention: tDCS (2 mA) with anode over AF4 and cathode over PZ (P‐F+)
Number of subjects: 16
Study 22264426 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Care Model (CCM) treatment
Number of subjects: 1823
Study 22264426 — intervention group
Group type: COMPARATOR
Intervention: Standard care (not explicitly mentioned but implied as control)
Number of subjects: 1823
Study 19129382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Number of subjects: 0
Study 17088024 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg cortisol
Number of subjects: 18
Study 17088024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15734714 — intervention group
Group type: EXPERIMENTAL
Intervention: ASLF bread breakfast
Number of subjects: 11
Study 15734714 — intervention group
Group type: COMPARATOR
Intervention: Standard white bread breakfast
Number of subjects: 11
Study 12065562 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered stress management training
Number of subjects: 411
Study 12065562 — intervention group
Group type: COMPARATOR
Intervention: Professionally administered stress management training
Number of subjects: 411
Study 12065562 — intervention group
Group type: COMPARATOR
Intervention: Usual psychosocial care only
Number of subjects: 411
Study 9797599 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG with low osmolarity oral rehydration solution (224 mosmol/l)
Number of subjects: 0
Study 9797599 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced osmolarity oral rehydration solution (224 mosmol/l)
Number of subjects: 0
Study 7894828 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination (HBV)
Number of subjects: 0
Study 7894828 — intervention group
Group type: COMPARATOR
Intervention: Control non vaccinated zone (NVZ)
Number of subjects: 0
Study 2203243 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil (200 mg/day twice daily)
Number of subjects: 12
Study 2203243 — intervention group
Group type: EXPERIMENTAL
Intervention: CERM 4205 (200 mg/day twice daily)
Number of subjects: 12
Study 2203243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2203243 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil
Number of subjects: 12
Study 2203243 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline
Number of subjects: 12
Study 2203243 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 12
Study 1009279 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure screening measurement
Number of subjects: 85
Study 1009279 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous blood pressure measurement
Number of subjects: 85
Study 1009279 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension control
Number of subjects: 85
Study 31093796 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral screen after MMF
Number of subjects: 60
Study 31093796 — intervention group
Group type: COMPARATOR
Intervention: MMF only (Control)
Number of subjects: 60
Study 28085793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 939
Study 25990454 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat non-dairy meal supplemented with milk (HFM meal)
Number of subjects: 19
Study 25990454 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat dairy meal (HFD meal)
Number of subjects: 19
Study 25990454 — intervention group
Group type: COMPARATOR
Intervention: High-fat non-dairy control meal (HFC meal)
Number of subjects: 19
Study 25990454 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meals (HFM, HFD, HFC)
Number of subjects: 19
Study 23269772 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (second cycle)
Number of subjects: 12
Study 21359235 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-point acupuncture
Number of subjects: 20
Study 21359235 — intervention group
Group type: COMPARATOR
Intervention: Four-point acupuncture
Number of subjects: 20
Study 19280523 — intervention group
Group type: EXPERIMENTAL
Intervention: Schisandra chinensis extract (SchE) 300 mg twice daily for 14 days
Number of subjects: 12
Study 19280523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) 120 mg three times daily for 14 days
Number of subjects: 12
Study 19280523 — intervention group
Group type: COMPARATOR
Intervention: Talinolol alone (control)
Number of subjects: 12
Study 16906641 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole 2% gel applied four times daily for 2 weeks
Number of subjects: 24
Study 16906641 — intervention group
Group type: COMPARATOR
Intervention: Zataria multiflora 0.1% gel applied four times daily for 2 weeks
Number of subjects: 24
Study 12463384 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 12463384 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 40
Study 10490157 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose fentanyl (15 microg x kg(‐1))
Number of subjects: 60
Study 10490157 — intervention group
Group type: COMPARATOR
Intervention: Low dose fentanyl (1 microg x kg(‐1))
Number of subjects: 60
Study 8725888 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy with leuprolide plus flutamide
Number of subjects: 0
Study 8725888 — intervention group
Group type: COMPARATOR
Intervention: Finasteride treatment
Number of subjects: 0
Study 1759789 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release verapamil (240 mg/24 h)
Number of subjects: 45
Study 1759789 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg, 50 mg/24 h)
Number of subjects: 45
Study 1759789 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sustained release verapamil + captopril
Number of subjects: 45
Study 1759789 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release verapamil
Number of subjects: 45
Study 1759789 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 45
Study 6349744 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy followed by chemotherapy using doxorubicin (Adriamycin) and 5-fluorouracil
Number of subjects: 129
Study 6349744 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy alone
Number of subjects: 129
Study 31332027 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diets (four different diets varying in macronutrient intake)
Number of subjects: 264
Study 31332027 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 264
Study 29052691 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Multistep Medication Review (3MR)
Number of subjects: 426
Study 29052691 — intervention group
Group type: COMPARATOR
Intervention: Standard procedures (Control)
Number of subjects: 426
Study 26076022 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal formula Yishen Huazhuo decoction (YHD)
Number of subjects: 144
Study 26076022 — intervention group
Group type: COMPARATOR
Intervention: Donepezil hydrochloride (DH) 5 mg/day
Number of subjects: 144
Study 25311881 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy corner store intervention
Number of subjects: 767
Study 25311881 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 767
Study 22173933 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg/d for 1 week, then 10 mg twice daily)
Number of subjects: 35
Study 22173933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 19574961 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine plus atenolol (N/A group)
Number of subjects: 94
Study 19574961 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine, atenolol, and metformin (N/A/M group)
Number of subjects: 94
Study 19574961 — intervention group
Group type: COMPARATOR
Intervention: Difference in BW before and after treatment between the two groups
Number of subjects: 94
Study 17305301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol infusion (0.5 g ethanol/kg body weight/24 hours)
Number of subjects: 44
Study 17305301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol infusion
Number of subjects: 44
Study 17305301 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 15071723 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral ibandronate (2.5 mg/day)
Number of subjects: 2946
Study 15071723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent oral ibandronate (20 mg every other day for 12 doses every 3 months)
Number of subjects: 2946
Study 15071723 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily and intermittent oral ibandronate
Number of subjects: 2946
Study 15071723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2946
Study 11642557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ariston pHc
Number of subjects: 31
Study 11642557 — intervention group
Group type: COMPARATOR
Intervention: Solitaire I
Number of subjects: 31
Study 9633845 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive surgical staging and disease removal alone
Number of subjects: 0
Study 9633845 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 0
Study 7612732 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPD (uninterrupted)
Number of subjects: 68
Study 7612732 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis
Number of subjects: 68
Study 7612732 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPD
Number of subjects: 68
Study 7612732 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 68
Study 7612732 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPD (predialysis)
Number of subjects: 68
Study 7612732 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPD (postdialysis)
Number of subjects: 68
Study 2682123 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 53
Study 2682123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 971011 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered protocol for headache management
Number of subjects: 203
Study 971011 — intervention group
Group type: COMPARATOR
Intervention: Physician-control group
Number of subjects: 203
Study 31228203 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of FOLFOX4 or CAPOX
Number of subjects: 1115
Study 31228203 — intervention group
Group type: COMPARATOR
Intervention: 6 months of FOLFOX4 or CAPOX
Number of subjects: 1115
Study 31228203 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of FOLFOX4
Number of subjects: 1115
Study 31228203 — intervention group
Group type: COMPARATOR
Intervention: 6 months of FOLFOX4
Number of subjects: 1115
Study 31228203 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of CAPOX
Number of subjects: 1115
Study 31228203 — intervention group
Group type: COMPARATOR
Intervention: 6 months of CAPOX
Number of subjects: 1115
Study 28575566 — intervention group
Group type: EXPERIMENTAL
Intervention: MTP plus IHHT (experimental group - EG)
Number of subjects: 34
Study 28575566 — intervention group
Group type: COMPARATOR
Intervention: MTP plus placebo (control group - CG)
Number of subjects: 34
Study 26272871 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (DHA+EPA)
Number of subjects: 103
Study 26272871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 23265686 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive verbal suggestion about pain being beneficial to muscles
Number of subjects: 0
Study 23265686 — intervention group
Group type: COMPARATOR
Intervention: Negative verbal suggestion about the aversive nature of the task
Number of subjects: 0
Study 23265686 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (opioid antagonist)
Number of subjects: 0
Study 23265686 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant (cannabinoid antagonist)
Number of subjects: 0
Study 23265686 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone and Rimonabant combined
Number of subjects: 0
Study 21292702 — intervention group
Group type: EXPERIMENTAL
Intervention: Rich media job aids
Number of subjects: 50
Study 21292702 — intervention group
Group type: COMPARATOR
Intervention: Traditional job aids
Number of subjects: 50
Study 19858385 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 206
Study 19858385 — intervention group
Group type: EXPERIMENTAL
Intervention: RT and AST combined
Number of subjects: 206
Study 19858385 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing PSA velocity at recurrence
Number of subjects: 206
Study 19858385 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe comorbidity score
Number of subjects: 206
Study 19858385 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA velocity at recurrence
Number of subjects: 206
Study 16766329 — intervention group
Group type: EXPERIMENTAL
Intervention: M. vaccae vaccine (two subcutaneous injections 3 months apart)
Number of subjects: 20
Study 16766329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15638973 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (Nasonex)
Number of subjects: 48
Study 15638973 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone sodium phosphate (Betnesol)
Number of subjects: 48
Study 15638973 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 48
Study 15638973 — intervention group
Group type: COMPARATOR
Intervention: Morning salivary cortisol (MSC)
Number of subjects: 48
Study 11422585 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric ultrasonic instrument
Number of subjects: 30
Study 11422585 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetostrictive ultrasonic instrument
Number of subjects: 30
Study 11422585 — intervention group
Group type: COMPARATOR
Intervention: Hand curette
Number of subjects: 30
Study 9322981 — intervention group
Group type: COMPARATOR
Intervention: L-NAME (3.0 microg x kg(‐1) x min(‐1) for 90 minutes) after placebo pretreatment
Number of subjects: 7
Study 9322981 — intervention group
Group type: COMPARATOR
Intervention: L-NAME (3.0 microg x kg(‐1) x min(‐1) for 90 minutes) after losartan pretreatment (50 mg)
Number of subjects: 7
Study 8486881 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of quinine taken at bedtime
Number of subjects: 16
Study 3404455 — intervention group
Group type: EXPERIMENTAL
Intervention: LY-171883 50 mg
Number of subjects: 12
Study 3404455 — intervention group
Group type: EXPERIMENTAL
Intervention: LY-171883 200 mg
Number of subjects: 12
Study 3404455 — intervention group
Group type: EXPERIMENTAL
Intervention: LY-171883 400 mg
Number of subjects: 12
Study 3404455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30391694 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index (GI; fructose) high-protein breakfast
Number of subjects: 19
Study 30391694 — intervention group
Group type: COMPARATOR
Intervention: High glycemic index (GI; glucose) high-protein breakfast
Number of subjects: 19
Study 28801422 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative semi-structured interviews with trial site staff
Number of subjects: 11
Study 25616671 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI
Number of subjects: 0
Study 25616671 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 0
Study 24334179 — intervention group
Group type: EXPERIMENTAL
Intervention: Crofelemer 125 mg twice daily
Number of subjects: 376
Study 24334179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study 21365028 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal plate preservation (BPP)
Number of subjects: 16
Study 21365028 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 16
Study 18390891 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 156
Study 18390891 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 156
Study 18390891 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Benazepril and Valsartan)
Number of subjects: 156
Study 18390891 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment mentioned)
Number of subjects: 156
Study 21843712 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Amyloid A (SAA)
Number of subjects: 152
Study 21843712 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 152
Study 21843712 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 152
Study 21843712 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Amyloid A (SAA), C-reactive protein (CRP), Procalcitonin (PCT)
Number of subjects: 152
Study 16186435 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex surveillance
Number of subjects: 594
Study 16186435 — intervention group
Group type: COMPARATOR
Intervention: Clinical surveillance
Number of subjects: 594
Study 11833550 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (Oxis) Turbuhaler plus Budesonide (Pulmicort) Turbuhaler
Number of subjects: 338
Study 11833550 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (Pulmicort) Turbuhaler alone
Number of subjects: 338
Study 11833550 — intervention group
Group type: COMPARATOR
Intervention: Conventional non-corticosteroid therapy
Number of subjects: 338
Study 11475742 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlicin 60 mg
Number of subjects: 55
Study 11475742 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin 5 mg
Number of subjects: 55
Study 7652690 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPU (150 mg)
Number of subjects: 0
Study 7652690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2547858 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 200 micrograms twice daily
Number of subjects: 39
Study 2547858 — intervention group
Group type: COMPARATOR
Intervention: Nedocromil sodium (NED) 4 mg twice daily
Number of subjects: 39
Study 22421 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-hydroxy-11-deoxycorticosterone (120 microgram intravenously in 1 h)
Number of subjects: 7
Study 22421 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone (80 microgram)
Number of subjects: 7
Study 22421 — intervention group
Group type: COMPARATOR
Intervention: Glucose (50 g/l; control)
Number of subjects: 7
Study 773198 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (2 gm, approximately 30 mg/kg)
Number of subjects: 95
Study 773198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 28614163 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval exercise (HIIE): 10 × 60 seconds at 90% of maximal velocity (MV) with 60 seconds of active recovery at 30% of MV
Number of subjects: 15
Study 28614163 — intervention group
Group type: COMPARATOR
Intervention: Continuous exercise (CE): 20 minutes at 60% of maximal velocity (MV)
Number of subjects: 15
Study 29383953 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (ICBT)
Number of subjects: 84
Study 29383953 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face group cognitive behavioural therapy (GCBT)
Number of subjects: 84
Study 27106105 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 989
Study 27106105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 989
Study 24453130 — intervention group
Group type: COMPARATOR
Intervention: 800 mg of Calcium (Ca)
Number of subjects: 300
Study 24453130 — intervention group
Group type: COMPARATOR
Intervention: 800 mg of Calcium with 3.6 g of short-chain fructo-oligosaccharides (CaFOS)
Number of subjects: 300
Study 24453130 — intervention group
Group type: EXPERIMENTAL
Intervention: maltodextrin
Number of subjects: 300
Study 24453130 — intervention group
Group type: COMPARATOR
Intervention: CaFOS in women with osteopenia
Number of subjects: 300
Study 22704364 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.05 mg/kg)
Number of subjects: 20
Study 22704364 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 21049601 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MP) and mouse nerve growth factor (mNGF) for injection
Number of subjects: 43
Study 21049601 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone sodium succinate (MP) only
Number of subjects: 43